Aeromics
Aeromics, a Cleveland-based company, develops AER-271, a drug targeting brain water channels for stroke-related cerebral edema treatment.
Founded
2006Aeromics, a Cleveland-based company, develops AER-271, a drug targeting brain water channels for stroke-related cerebral edema treatment.
Aeromics, founded in Cleveland, focuses on developing innovative treatments for cerebral edema associated with severe ischemic stroke. The company's core mission is to leverage groundbreaking discoveries in water physiology, specifically targeting aquaporins—proteins forming water channels in cells. Aeromics' flagship product, AER-271, aims to control brain water channels to mitigate the effects of cerebral edema. Their vision is to revolutionize anti-edema therapy, improving patient outcomes in stroke, spinal cord injury, and CNS surgery.
Notable figures affiliated with Aeromics include Peter Agre, whose Nobel Prize-winning discovery of aquaporins underpins the company's scientific approach. The company has attracted significant interest from investors due to its potential to address unmet medical needs in stroke treatment. Key achievements include advancing AER-271 through clinical trials, demonstrating its efficacy and safety. Overall, Aeromics is poised to make a substantial impact on the treatment of life-threatening conditions related to water imbalance in the brain.
Companies similar to Aeromics include Aer Therapeutics, Basking Biosciences, Aerwave Medical and Astria Biosciences.
Aeromics was founded in 2006.
Aeromics' headquarters is located in Cleveland, OH, US.
Aeromics' most recent funding round was for $9.4M (USD) in October 2017.
As of Oct 19, 2017, Aeromics has disclosed funding of $12.6M (USD). Undisclosed round amounts are excluded.
Aeromics has 6 employees as of Feb 5, 2024.
Astria Biosciences
